Physician profile
Brian C Orr
NPI 1437478146
$2,688.75
in general payments reported to CMS, 2019-2025
11 companies · $25.70 in 2025
The $25.70 reported for 2025 was less than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $246 · 2020: $142 · 2021: $2,019 · 2023: $61.49 · 2024: $195 · 2025: $25.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $239 · Education: $43.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $238.69 |
| Education | $43.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $1,925.00 | 2021 | |
| Clovis Oncology, INC. | $240.48 | 2019-2020 | |
| Abbvie INC. | $125.57 | 2024 | |
| Tesaro, INC. | $124.99 | 2019 | |
| Myriad Genetic Laboratories, INC. | $115.80 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $71.33 | 2023-2024 | Gemtesa |
| Merck Sharp & Dohme LLC | $58.85 | 2023-2025 | Keytruda, Lynparza |
| Ethicon US, LLC | $26.73 | 2023 | Stratafix, Enseal X1 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Orr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.